Eupraxia Pharmaceuticals Inc.
EPRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $23,123 | $20,363 | $13,630 | $7,591 |
| G&A Expenses | $15,710 | $7,484 | $3,988 | $6,970 |
| SG&A Expenses | $15,710 | $7,484 | $3,988 | $6,970 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $87 |
| Operating Expenses | $38,833 | $27,847 | $17,617 | $14,649 |
| Operating Income | -$38,833 | -$27,847 | -$17,617 | -$14,649 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1,813 | -$1,082 | -$1,373 | -$3,680 |
| Pre-Tax Income | -$37,020 | -$28,930 | -$18,991 | -$18,329 |
| Tax Expense | $3 | $36 | $0 | $0 |
| Net Income | -$36,675 | -$28,221 | -$18,490 | -$18,031 |
| % Margin | – | – | – | – |
| EPS | -0.76 | -1.17 | -0.96 | -1.61 |
| % Growth | 35% | -21.9% | 40.4% | – |
| EPS Diluted | -0.76 | -1.17 | -0.96 | -1.61 |
| Weighted Avg Shares Out | 33,931 | 24,147 | 19,285 | 14,243 |
| Weighted Avg Shares Out Dil | 33,931 | 24,147 | 19,285 | 14,243 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,668 | $863 | $432 | $52 |
| Interest Expense | $868 | $1,170 | $983 | $1,017 |
| Depreciation & Amortization | $247 | $156 | $148 | $87 |
| EBITDA | -$35,905 | -$27,604 | -$17,860 | -$17,224 |
| % Margin | – | – | – | – |